AIDS Research and Human Retroviruses · 1995 · 153 citations · 19 references
Life SciencesImmunologyInfectious DiseasesCellular ImmunologyClinical ImmunologyImmunology Of Infectious DiseasesCell-mediated ImmunityCellular Immunity In InfectionCytotoxic T Lymphocyte ResponsesImmunodeficiency DisordersT Cell ActivationT Cell BiologyAids-defining InfectionsCytotoxic T Lymphocyte FunctionDisease Progression PredictionHiv Envelope Glycoprotein AntigensRelative Risk EstimationRelative Risk ReductionT-cell Immune ResponsesViral-specific Cytotoxic T Lymphocyte Responses
The duration of human immunodeficiency virus (HIV-1) infection prior to the development of AIDS is variable, and for most patients the exact time of infection is not known. A group of 38 HIV-1-infected subjects was tested while asymptomatic for comparative cytotoxic lymphocyte responses to the Gag and envelope antigens of HIV-1. Twenty of the 38 patients had no detectable primary cytotoxic T lymphocyte (CTL) response to Gag, and this was associated with a relative risk of 1.89 for progression to ARC or AIDS during the subsequent 3 to 40 months of observation when compared with patients who had Gag-specific CTL activity at the beginning of the observation period. In contrast, no significant association was observed between envelope-specific cytotoxic activity and disease progression. Other patient characteristics, including CD4+ T lymphocyte counts and antibody levels to the p24gag protein, measured at the start of observation, did not correlate with disease progression during the observation period. This suggests that the anti-Gag CTL response may be protective during HIV-1 infection.
19
HIV-specific cytotoxic T lymphocytes in seropositive individuals
Bruce D. Walker, Sekhar Chakrabarti, Bernard Moss et al. · Nature · 1987 · 783 citations
MEASLES AS AN INDEX OF IMMUNOLOGICAL FUNCTION
F. M. Bürnet · The Lancet · 1968 · 275 citations